Fundraising FoxARCH Venture Partners — 2015 Investments
15 investments dated 2015 · listed companies and verified rows first · show all
908 Devices manufactures handheld mass spectrometry and chemical analysis devices for rapid detection in defense, security, and hazardous materials response applications.
Deep TechDefense TechHardwareMedical DevicesBoston, US
Kevin J. Knopp, PhD(CEO & Co-founder)Christopher Brown(Executive Officer)inKevin Knopp(Executive Officer, Director)inJoseph Griffith IV(Executive Officer)
BoardCorey Steffek(Director)
Board seatKeith CrandellKevin Hrusovsky· per SEC Form D
Co-investorsIn-Q-TelRazor's Edge VenturesUTECAramco VenturesARK Investment ManagementBlackRock+4 more
Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)inTimothy Springer(Director)David Hallal(Chief Executive Officer, Chairman and Director)inAkshay Vaishnaw(President of Research & Development and Director)inR. Keith Woods(Chief Operating Officer)inVikas Sinha(Chief Financial Officer)in
Board seatKristina Burow· per SEC Form D
Co-investorsAisling CapitalEcoR1 CapitalPolaris PartnersThe Kraft Group
Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.
BiotechDeep TechSemiconductorsSouth San Francisco, US
William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Emily Leproust(Founder)inEmily Leproust, PhD(CEO and Co-Founder of Twist)Patrick Finn(President and Chief Operating Officer)inAdam Laponis(Chief Financial Officer)in
Board seatKeith Crandell· per SEC Form D
Co-investors+ND Capital3E Bioventures CapitalAsset Management CompanyATEL VenturesBay City CapitalBlack Opal Ventures+10 more
US agricultural biotech that discovered microbe-based crop protection products; its assets were sold to Certis Biologicals and Ginkgo Bioworks in 2024.
AgTechResearch Triangle Park, US
Scott Uknes(Manager)inEric Ward(Manager)Paul Schulze-Lefert(President)Michael Koziel(Vice President and Manager)
BoardThomas Dietz(Manager)
Board seatKristina Burow· per SEC Form D
Co-investorsAliment CapitalBlue Horizon CorporationPontifax AgTechBill & Melinda Gates FoundationLeaps by BayerNovalis LifeSciences+1 more
Cooledge designs and manufactures specialized lighting solutions including LED luminaires, tunable white products, and architectural lighting systems for commercial and industrial applications.
Advanced ManufacturingCleantechConstruction TechHardwareRichmond, US
BillCalvin Wade Sheen(Executive Officer, Director)
BoardWilliam Sims(Director)Kirk A. Washington(Director)Geoff Catherwood(Director)inThomas Bilbrough(Director)
Board seatClinton Bybee· per SEC Form D
Co-investorsSaints CapitalYaletown PartnersBDC Venture Capital
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardAmir Nashat(Director)in
Board seatKristina BurowRichard Heyman· per SEC Form D
Co-investorsage1EcoR1 CapitalLAVLifeSci Venture PartnersLilly Asia VenturesNew Enterprise Associates (NEA)+8 more
Nanosys develops Quantum Dot technology and materials, providing samples, R&D collaboration, and scaled production for partners building display and other advanced-material products.
Advanced ManufacturingDeep TechHardwareNew MaterialsSemiconductorsMilpitas, US
Jason Hartlove(Executive Officer, Director)inJian Chen(Executive Officer)inRussell Kempt(Executive Officer)inNoland Granberry(Executive Officer)inDr. Martin Devenney(Co Chief Executive Officer and Assistant Secretary)Dr. Hirokazu Sasaki(President & CEO and Treasurer, Shoei Electronic Materials, Inc. • Operating Officer & Division Manager QD Business Dept., Shoei Chemical, Inc.)
Board seatKeith Crandell· per SEC Form D · $10M raise · filed Mar 2015
Co-investorsArcher Capital GroupArcher Venture CapitalProspect Venture PartnersStructural CapitalTEL Venture Capital, Inc.Venrock+4 more
Company producing world's first multi-material 3D printer capable of printing functional features with variable material properties.
Somerville, US
Jennifer A. Lewis(Executive Officer, Director)
BoardJiong Ma(Director)
Board seatClinton Bybee· per SEC Form D
Co-investorsBraemar Energy VenturesIn-Q-TelOUP (Osage University Partners)
Subsea and terrestrial optical transport supplier whose assets, rescued by H.I.G. in 2017, are being bought by Prysmian and Fincantieri.
Allen, US
Keith Henderson(Executive Officer)inLes Barkley(Executive Officer)inPaul Colan(Executive Officer)inJon Hopper(Executive Officer, Director)inGary Otake(Executive Officer)inHerve Fevrier(Executive Officer)
Board seatClinton Bybee· per SEC Form D
Co-investorsAristos VenturesNew Enterprise Associates (NEA)Wellcome Trust
Cambridge, MA clinical-stage biotech developing engineered exosome therapeutics; IPO'd on NASDAQ in 2020, later restructured.
BiotechSeattle, US
Doug Williams(Executive Officer, Director)in
BoardNoubar Afeyan(Director)inSteven Gillis(Director)Eric Lander(Director)
Co-investorsEcoR1 CapitalAlexandriaFidelity InvestmentsFlagship PioneeringQatar Investment Authority
Nimbus Therapeutics is a biotechnology company that designs precision small molecule medicines using a computational, multidisciplinary drug discovery approach.
AI & Machine LearningBiotechDeep TechHealthtech
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesDementia Discovery FundGV (Google Ventures)Lightstone Ventures+4 more
Cambridge, MA biotech developing stem cell-derived islet therapy plus an immune-protective device for type 1 diabetes; acquired by Vertex for $950M.
BiotechCambridge, US
Robert Millman(Executive Officer, Director)
BoardTodd Foley(Executive Officer, Director)inMitch Finer(Director)Stephen Knight(Director)inJim Scopa(Director)William Sahlman(Director)
Co-investorsF-Prime CapitalJDRF T1D FundORI CapitalSlater Technology Fund6 Dimensions CapitalCowen Healthcare Investments+4 more
VBI Vaccines is a biopharmaceutical company developing vaccine candidates using virus-like particle (VLP) platforms, including proprietary enveloped VLP and mRNA-launched eVLP technologies.
BiotechHealthtechCambridge, US
Marc Kirchmeier(Vice President, Formulation Development)Egidio Nascimento(Chief Financial Officer)inDavid Anderson(Senior Vice President, Research)inJeff Baxter(President and Chief Executive Officer)inAdam T. Buckley(Vice President, Business Development)inMurray G. Smith(Executive Officer)
Co-investors5AM VenturesClarus VenturesK2 HealthVentures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.